Scientific References Check out the scientific literature that supports our molecular targets and our synthetic lethal approach. April 2023 Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers Adam Petrone, Elia Aguado-Fraile, Et Al. AACR 2023 September 2022 Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ Monica Bubenik, Pavel Mader, Et Al. Journal of Medicinal Chemistry July 2022 Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306 Janek Szychowski, Robert Papp, Et Al. American Chemical Society July 2022 Guiding ATR and PARP inhibitor combinationswith chemogenomic screens Zimmermann M, Bernier C, Et Al. Cell Reports April 2022 CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition Gallo D, Young JTF, Fourtounis J, et al. Nature February 2022 RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors Roulston A, Zimmermann M, Papp R, et al. Molecular Cancer Therapeutics June 2020 Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity Sokolova AO, Yu EY, Cheng HH Clinical Cancer Research May 2020 Identifying functional loss of ATM gene in patients with advanced cancer Pilie PG, Gheeya JS, Kyewalabye K, et al. ASCO February 2020 Analyse pan-cancer de génomes entiers Consortium ICGC/TCGA pour l'analyse pancancer du génome entier Nature February 2020 Pan-cancer analysis of whole genomes ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium Nature 1234 We have a number of synthetic lethal therapies in development. View Pipeline
